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Edited by Varda RotterAbstract The tumor suppressor and transcription factor p53 is
a key modulator of cellular stress responses and can trigger
apoptosis in many cell types, including neurons. In this study,
we have shown that the Microtubule-Associated Protein 1B
(MAP1B) light chain can interact with the tumor suppressor
p53. We also demonstrate that both p53 and the MAP1B light
chain (MAP1B-LC1) alter their localization from the cytoplasm
to the nucleus when neuroblastoma cells, SH-SY5Y, are treated
with doxorubicin. Additionally, we demonstrate that the
MAP1B-LC1 negatively regulates p53-dependent transcrip-
tional activity of a reporter construct driven by the p21 pro-
moter. Consequently, MAP1B-LC1 binds to p53 and this
interaction leads to the inhibition of doxorubicin-induced apopto-
sis in SH-SY5Y cells.
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doi:10.1016/j.febslet.2008.07.021and is essential during the elongation phase of axon formation
[1,2]. MAP1B controls the direction of growth cone migration
and neurons that lack MAP1B are characterized by an increase
in terminal and collateral branching and an impaired turning
of growth cones [3–6]. MAP1B consists of 2464 amino acids
and is synthesized as a polyprotein precursor which is rapidly
cleaved to give rise to the respective heavy and light chains,
termed MAP1B-HC and MAP1B-LC1 [7]. The site of proteo-
lytic cleavage within the MAP1B precursor has been narrowed
down to a region in the proximity of amino acid 2210 [8].
However, the proteolytic cleavage enzyme responsible for this
event has not yet been identiﬁed. Both MAP1B-HC and
MAP1B-LC1 have microtubule binding domains (MTB) and
the capacity to cross-link microtubules by their direct interac-
tion with both tubulin and actin [2].
Because MAP1B interacts with a wide variety of proteins,
there is growing consideration that MAP1B plays a crucial role
in cytoskeleton stability and may also have a role in other cel-
lular functions as well. To maintain microtubule stability,
MAP1B interacts with several other proteins such as gigaxonin,
a protein that links microtubules and intermediate ﬁlaments [9];
myelin-associated glycoprotein (MAG), required for cytoskele-
ton formation of glial cells [10,11]; and SCG10, essential in neu-
rite outgrowth and modulation of microtubule disassembly
[12]. MAP1B also interacts with the rho1 subunit of the GA-
BAC receptor at neuronal synapses [13–15]. Being anchored
to the cytoskeleton via MAP1B lowers the sensitivity of GA-
BAC receptors in the inhibitory synapses and provides a func-
tional modulation of these neuronal receptors. Although
most studies of MAP1B have focused on its interaction with
microtubules, other roles have been proposed independent of
its microtubule-associated function. MAP1B directly binds
with glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
essential in the local energy provision of cytoskeletal structures,
and helps to keep this enzyme in close proximity to the cyto-
skeleton [16]. Recently, MAP1B-LC1 has also been identiﬁed
as an interacting partner of Pes1, which is required for ribo-
some biogenesis and cell proliferation [17]. The interaction with
MAP1B-LC1 induces a cytoplasmic sequestration of nucleolar
Pes1, which results in a reduction of cell proliferation. Thus,
MAP1B-LC1 acts as a negative regulator of Pes1. Although
MAP1B plays important roles in stability of the cytoskeleton
and other cellular functions, the exact underlying molecu-
lar mechanisms associated with MAP1B function remains
unclear.blished by Elsevier B.V. All rights reserved.
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control, apoptosis, diﬀerentiation, DNA repair, and recombi-
nation [18,19]. In response to DNA damage, p53 accumulates
in the nucleus [20] where it transcriptionally activates the genes
that encode p21, BAX, PUMA, and MDM2, as well as other
genes that are involved in growth arrest and apoptosis [21].
Neuroblastoma is one of the most common malignancies
occurring during childhood. It derives from the neural crest,
which gives rise to multiple cell lineages with neuronal or mel-
anocytic phenotypes [22]. Unlike other tumor types, almost all
human neuroblastomas were found to carry a wild-type p53
gene [23]. Instead of mutation, cytoplasmic sequestration of
p53 has been proposed as an alternative mechanism of inacti-
vation in neuroblastoma cells. However, some DNA damaging
agents, such as doxorubicin and etoposide, induce nuclear
accumulation of p53 in SH-SY5Y neuroblastoma cells
[24,25]. After the drug treatment, p53 protein increases its
expression level and accumulates in the nucleus, leading to
the induction of its transcription targets p21 and MDM2.
Thus, as a chemotherapeutic approach, enhancing drug-in-
duced apoptosis via p53 activation may be an eﬃcient strategy
for treatment of neuroblastoma.
This study was undertaken to investigate the possible eﬀects
of MAP1B-LC1 on doxorubicin-induced apoptosis in the neu-
roblastoma cell line, SH-SY5Y. We report that MAP1B-LC1
binds to the p53 transactivation and oligomerization domains
and inhibits p53 transcriptional activity. Our ﬁndings suggest
that the MAP1B-LC1 acts as a negative regulator of both
p53 transactivation and doxorubicin-induced apoptosis via
the MAP1B-LC1/p53 interaction in neuroblastoma cells.2. Materials and methods
2.1. Cell culture and transfection
SH-SY5Y and HEK 293 cells were obtained from the ATCC (Amer-
ican type culture collection, Manassas, VA) and maintained in Dul-
beccos modiﬁed Eagles medium supplemented with 10% fetal
bovine serum (Invitrogen; Carlsbad, CA) and penicillin–streptomycin
(50 U/ml). Doxorubucin was purchased from Sigma–Aldrich (St.
Louis, MO). Transient transfection was performed by Lipofectamine
2000 (Invitrogen) with diﬀerent plasmid DNA according to the manu-
facturers instructions.
2.2. In vivo binding assay and Western blotting
SH-SY5Y cells were seeded in 100 mm plates at an initial density of
2 · 106 cells and allowed to grow for 12 h. The cells were treated with
2 lM doxorubicin for 24 h, and lysed in a buﬀer containing 1% Triton
X-100, 150 mM NaCl, 50 mM Tris–HCl, pH 7.5, 0.1% SDS, 1% Non-
idet P-40, and 1 mM PMSF. The cell suspensions were incubated on
ice for 20 min and centrifuged at 12,000 rpm at 4 C for 20 minutes.
For immunoprecipitation assays, the supernatants were pre-cleaned
with 20 ll of protein A/G or protein A agarose bead (50% slurry)
and then incubated at 4 C overnight with 30 ll of fresh protein A/G
bead in the presence of appropriate antibodies. The beads were washed
three times in PBS, resuspended in SDS sample buﬀer, and boiled for
10 min. Samples were analyzed by Western blotting using the appro-
priate antibodies to detect protein expression. The MAP1B and p53
protein were detected by each primary antibody (DO-1, #sc-126 or
C-19, #sc-1311, Santa Cruz Biotechnology) and secondary antibody
(HRP-anti-goat and -anti rabbit, 1:5000 dilution). The polyclonal
GFP, p21, Bax, PARP, a-tubulin and b-tubulin antibodies were from
Santa Cruz Biotechnology. Western blot was detected by chemolumi-
nescence (ECL, Santa Cruz Biotechnology).
2.3. Immunoﬂuorescence staining and confocal microscopic detection
SH-SY5Y cells were grown on a sterile coverslips in 60 mm dishes
and treated with doxorubicin. After the doxorubicin treatment, cellswere washed with PBS and ﬁxed for 1 h in 4% paraformaldehyde.
The cells were permeabilized with 0.3% Triton X-100 for 20 min, incu-
bated with a primary antibody in blocking solution for 3 h at room
temperature, washed in blocking solution, and then incubated with
the appropriate secondary antibody for 30 min. Primary antibodies
were used at 1:100 for p53 (FL-393: Santa Cruz) and 1:100 for MAP1B
(C-20: Santa Cruz Biotechnology). Cy3-conjugated goat anti-rabbit
IgG (1:200, Amersham Biosciences) and FITC-conjugated rabbit
anti-goat IgG (1:200, Santa Cruz Biotechnology) were used as second-
ary antibodies. DAPI (Sigma) was used for nuclear staining. Cells were
incubated in 300 nM DAPI in PBS for 2 min at room temperature.
Cells were visualized using a Radians 2000 microscope (Bio-Rad).
2.4. Luciferase assay
HEK 293 and SH-SY5Y cells were cultured in 60 mm dishes and
transfected with the ﬁreﬂy luciferase p21 reporter gene (0.1 lg) and
pCMV-b-galactosidase (0.1 lg) together with pEGFP-MAP1B-LC,
pcDNA-HA-53 and MAP1B siRNA using Lipofectamine 2000. After
24 h of transfection, cells were lysed in reporter lysis buﬀer (Promega).
Cell extracts were analyzed with the luciferase reporter assay system
using a Lumat LB 9501 Berthold Luminometer. Luciferase activities
of the p21-luciferase vector were normalized based on b-galactosidase
activity of the cotransfected vector.
2.5. Preparation of subcellular fractions
SH-SY5Y cells were washed with ice-cold PBS, harvested by centri-
fugation, and lysed in Buﬀer A (10 mM HEPES, pH 7.9, 10 mM KCl,
0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, and 1 mM phenylmeth-
ylsulfonyl ﬂuoride) for 15 min. For cell lysis 10% (v/v) of Nonidet P-40
was added, and the cells were vortexed for 10 s. After centrifugation at
5000 rpm for 30 s, the supernatant (cytosolic extracts) was transferred
to a new tube. The pellet was added to ice-cold Buﬀer C (20 mM
HEPES, pH 7.9, 0.4 M NaCl, 0.1 mM EDTA, 0.1 mM EGTA,
1 mM DTT, and 1 mM phenylmethylsulfonyl ﬂuoride), incubated
for 15 min at 4 C, and centrifuged at 14000 rpm for 5 min. The super-
natant (nuclear extracts) was transferred to new tubes and kept frozen
at 70 C until use.
2.6. Apoptosis assays and DNA fragmentation
Apoptotic cells were identiﬁed by their rounded morphology, com-
pared to the spread-out morphology of non-apoptotic cells. Chromatin
condensation as an apoptotic marker was visualized by Hoechst 33342
(Sigma–Aldrich) staining. For DNA fragmentation assay, SH-SY5Y
cells were transfected with GFP-MAP1B-LC and treated with doxoru-
bicin 2 lM. Thirty-six hours after treatment with doxorubicin, cells
were colleted. Samples are washed with phosphate buﬀered saline
and pelleted by centrifugation. The cell pellets are then treated for
10 s with lysis buﬀer (1% NP-40 in 20 mM EDTA, 50 mM Tris–HCl,
pH 7.5). After centrifugation for 5 min at 1600 · g, the supernatant
is collected. The supernatants were brought to 1% SDS and treated
for 2 h with RNase A at 56 C followed by digestion with proteinase
K for at least 2 h at 37 C. After addition of 10 M ammonium acetate,
the DNA is precipitated with 2.5 volume of ethanol, dissolved in gel
loading buﬀer, and separated by electrophoresis in 1.5% agarose gels.
2.7. Statistical analysis
Statistical analysis of variances between two diﬀerent experimental
groups was performed with Tukeys post-hoc comparison test using
SPSS (ver. 11.5). All experiments were repeated at least three times.
The levels are considered signiﬁcant for P < 0.01 (shown as **) and
very signiﬁcant for P < 0.001 (shown as ***).3. Results
3.1. MAP1B-LC1 interacts with p53 in SH-SY5Y cells in vivo
We have previously conﬁrmed that MAP1B-LC1 binds with
p53, and that overexpressed MAP1B-LC1 could negatively
regulate the transcriptional activity of p53 in HEK 293 cells
(unpublished data). Because MAP1B is highly expressed in
neuronal cells, we ﬁrst examined the endogenous interaction
of MAP1B-LC1 with p53 in the neuroblastoma cell line,
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Fig. 1. MAP1B-LC1 interacts with p53 in SH-SY5Y neuroblastoma cells in vivo. (A) The in vivo interaction between endogenous MAP1B-LC1 and
p53 was determined by immunoprecipitation using anti-p53 antibodies and rabbit-serum as a negative control. Western blot analysis indicated the
presence of MAP1B-LC1 and p53 using anti-MAP1B-LC and anti-p53 antibodies, respectively. (B) After SH-SY5Y cells were stimulated with 2 lM
doxorubicin for 24 h (lane 3), the in vivo interaction between endogenous MAP1B-LC1 and p53 was determined by immunoprecipitation and
Western blotting using the appropriate antibodies.
2828 S.-Y. Lee et al. / FEBS Letters 582 (2008) 2826–2832SH-SY5Y. Whole cell lysates from SH-SY5Y cells were co-
immunoprecipitated with anti-p53 antibodies and rabbit serum
as a negative control. The immunoprecipitated proteins were
then detected by Western blotting using speciﬁc anti-MAP1B
and anti-p53 antibodies (Fig. 1A). Thus, these results demon-
strated that endogenous p53 and MAP1B-LC1 interact in SH-
SY5Y cells.
It is reported that the chemotherapeutic agents, such as
doxorubicin and etoposide, induced p53-mediated apoptosis
in SH-SY5Y neuroblastoma cells. To investigate whether
MAP1B-LC1 interacts with p53 in doxorubicin-induced apop-
totic cells, SH-SY5Y cells were either untreated or treated with
2 lM doxorubicin for 24 h. Total cell lysates were immunopre-
cipitated with anti-p53 (lanes 2 and 3) together with their con-
trol rabbit serums (lane 1), and then Western blotting was
performed using anti-MAP1B or anti-p53 antibodies. As
shown in Fig. 1B, we clearly observed that MAP1B-LC1 was
speciﬁcally detected by immunoprecipitation with the anti-
p53 antibody (lane 2, upper panel) but not with the preimmune
rabbit serum (lane 1). We also detected that MAP1B-LC1
interacts more intensively with p53 in doxorubicin-treated cells
(lane 3) than in untreated cells (lane 2). These results suggested
that the physical interaction between MAP1B-LC1 and p53 in-
creased in doxorubicin treated SH-SY5Y cells in vivo.
3.2. MAP1B-LC1 and p53 change their localization to the
nucleus and both proteins interact in the nucleus when
treated with doxorubicin
To determine the localization of the MAP1B and p53 in
doxorubicin treated SH-SY5Y cells, we immuno-stained both
treated (2 lM doxorubicin) and untreated SH-SY5Y cells
using anti-MAP1B and anti-p53 antibodies. As shown in
Fig. 2A, immunoﬂuorescent staining revealed low levels of
p53 in the nucleus of untreated cells. After doxorubicin treat-
ment, there was an increase in nuclear staining of the p53 pro-
tein. Furthermore, cytoplasmic MAP1B-LC1 also translocated
to the nucleus in cells treated with doxorubicin.
To further conﬁrm the translocation of p53 and MAP1B-
LC1 by doxorubicin, SH-SY5Y cells were separated into nu-
clear and cytoplasmic fractions and the sub-cellular amounts
of both proteins were determined by Western blot analysis.
As shown in Fig. 2B, both p53 and MAP1B-LC1 changed theirlocalization from the cytoplasm to the nucleus when treated
with doxorubicin (upper panel). Each fraction was veriﬁed
by Western blotting using antibodies against the subcellular
marker proteins Rb (nuclear localized) and b-tubulin (cyto-
plasm localization) (Fig. 2B, low panel). The sub-cellular ex-
tracts were then immunoprecipitated with anti-p53
antibodies and Western blot analysis was performed using
anti-MAP1B and anti-p53 antibodies. Co-precipitation of
endogenous MAP1B-LC1 with p53 antibodies was higher in
the nuclear fraction after doxorubicin treatment. In contrast,
immunoprecipitated MAP1B-LC1 was signiﬁcantly reduced
in the cytoplasmic fraction of doxorubicin treated cells (Fig.
2B, middle panel). Taken together, these results indicate that
both p53 and MAP1B-LC1 change their localization to the nu-
cleus and the interaction between p53 and MAP1B-LC1 was
further increased within the nuclear fraction after doxorubicin
treatment.3.3. MAP1B-LC1 speciﬁcally interacts with the transactivation
and oligomerization domains of p53
To deﬁne the region of p53 that is required for the interac-
tion with MAP1B-LC1, HEK 293 cells were transfected with
the GFP empty vector or a p53 expression plasmids encoding
GFP-fused to full-length p53, the p53 transactivation domain
(TAD), the p53 DNA binding domain (DBD), or the p53 olig-
omerization domain (OD) (Fig. 3A) together with the HA-
tagged MAP1B-LC1 expression plasmid. After the whole cell
lysates were immunoprecipitated with anti-GFP antibodies,
Western blot analysis was performed with anti-HA and anti-
GFP antibodies. Although DBD-containing region (amino
acids 102–323) of p53 did not appear to interact with
MAP1B-LC1, the p53 TAD-containing region (amino acids
1–101) and OD-containing region (amino acids 324–393)
strongly interacted with MAP1B-LC1 (Fig. 3B). Therefore,
this demonstrated that MAP1B-LC1 interacts with both the
TAD and OD of p53.3.4. MAP1B-LC1 represses the transcriptional activity of p53
To examine whether or not MAP1B-LC1 could aﬀect p53-
dependent transcriptional activation through their interaction,
SH-SY5Y cells were transiently co-transfected with a p53
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S.-Y. Lee et al. / FEBS Letters 582 (2008) 2826–2832 2829expression plasmid plus a luciferase reporter plasmid contain-
ing the p53-responsive element from the p21 promoter. As
indicated in Fig. 4A, enhanced luciferase activities by p53
transactivation (lane 3) were repressed by MAP1B-LC1 over-
expression (lane 6). Indeed, transfection of MAP1B siRNA
into SH-SY5Y cells signiﬁcantly decreases the repressive eﬀectof both overexpressed GFP-MAP1B (lane 7) and endogenous
MAP1B (lane 5) expression. To further validate these results in
doxorubicin-induced apoptotic responses, SH-SY5Y cells were
treated with 2 lM of doxorubicin and transfected with
MAP1B-LC1 (Fig. 4B). The expression of MAP1B-LC1 also
repressed the p21-promoter containing luciferase activity in a
dose dependent manner that was induced by doxorubicin
treatment in SH-SY5Y cells. Taken together, these results sug-
gested that MAP1B-LC1 could negatively regulate the tran-
scriptional activity of p53.
3.5. The interaction between MAP1B-LC1 and p53 inhibits
doxorubicin-induced apoptosis in SH-SY5Y cells
Because MAP1B-LC1 inhibited the transcriptional activity
of p53, these results raised the possibility that MAP1B-LC1
may inhibit doxorubicin-induced apoptosis. To investigate
whether MAP1B-LC1 could reduce doxorubicin-induced p53
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Fig. 4. MAP1B-LC1 represses transcriptional activity of p53. (A) SH-
SY5Y cells were co-transfected with the combined expression plasmids
of HA-p53, GFP-MAP1B-LC or GFP, and siRNA of MAP1B,
together with a luciferase reporter plasmid containing the p21
promoter. Luciferase activities were measured 24 h after the transfec-
tion as described in Section 2. The data were normalized to b-
galactosidase activity and expressed as a relative-fold-increase of
luciferase units (RLU). Total protein expression of whole cell lysates
were detected by Western blotting using aniti-HA, GFP, MAP1B
antibodies. b-Tubulin expression served as a loading control. All data
are representative of three independent experiments, and statistical
signiﬁcance is represented by Tukeys post-hoc test (**P < 0.01;
***P < 0.001). (B) SH-SY5Y cells were transfected with GFP-
MAP1B-LC1 or GFP empty vector together with a luciferase reporter
plasmid containing the p21 promoter, and the cells were treated with
2 lM doxorubicin for 24 h. The data were normalized to b-galacto-
sidase activity and expressed as a relative-fold-increase of luciferase
units (RLU).
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and treated with 2 lM of doxorubicin. We then examined
the expression levels of endogenous p21 and Bax, which are
transcriptional target genes of p53, by immunoblot analysis.As shown in Fig. 5A, the expression levels of p21 and Bax were
increased by doxorubicin treatment. However, the increased
p21 and Bax levels were reduced by MAP1B-LC1 overexpres-
sion. These results suggested that MAP1B-LC1 repressed
doxorubicin-induced p53 activities by the interaction of
MAP1B-LC1 and endogenous p53.
To determine whether MAP1B-LC1 inhibits doxorubicin-in-
duced apoptosis, SH-SY5Y cells were treated with doxorubicin
for 36 h, and then genomic DNA was isolated and subjected to
agarose gel electrophoresis. The DNA isolated from doxorubi-
cin-treated cells showed a fragmented pattern, characteristic of
apoptosis, and this genomic DNA fragmentation was inhibited
in MAP1B-LC1 transfected cells (Fig. 5B). For further conﬁr-
mation of MAP1B-LC1-mediated apoptotic inhibition, we
examined the changes in cellular morphology and nuclear con-
densation (via Hoechst staining) in cells transfected with an
GFP empty vector. After doxorubicin treatment for 24 h, the
SH-SY5Y cells showed the characteristics of apoptotic mor-
phology and chromatin condensation. However, doxorubi-
cin-treated cells expressing MAP1B-LC1 showed a normal
morphology and diﬀusely stained, intact nuclei (Fig. 5C). Ta-
ken together, these results indicated that the MAP1B-LC1
interaction with p53 suppresses the transcriptional activity of
p53 and doxorubicin-induced apoptosis in SH-SY5Y neuro-
blastoma cells.4. Discussions
In this study, we have shown that MAP1B-LC1 interacts
with the tumor suppressor p53, and that it speciﬁcally binds
with the transactivation and oligomerization domains of p53.
We also demonstrated that both p53 and MAP1B-LC1 change
their localization from the cytoplasm to the nucleus and their
interaction was increased in the nuclear fraction, in doxorubi-
cin treated neuroblastoma cells. Indeed, we demonstrated that
the MAP1B-LC1 negatively regulated p53-dependent tran-
scriptional activity using a reporter driven by the p21 pro-
moter. Consequently, MAP1B-LC1 binds with p53 and this
interaction leads to the inhibition of doxorubicin-induced
apoptosis in SH-SY5Y cells.
Previous studies have demonstrated that MAP1B not only
forms cross-links between individual microtubules for stabiliz-
ing microtubule structure but can also interact with non-
microtubule-associated proteins that can regulate microtubule
stability [2]. It has been also reported that MAP1B has other
novel functions [17]. One novel function of MAP1B-LC1 is
that it interacts with Pes1 and induces a cytoplasmic sequestra-
tion of nucleolar Pes1, which results in a reduction of cell pro-
liferation. Thus, MAP1B-LC1 acts as a negative regulator of
Pes1.
Using a yeast two-hybrid assay, we have identiﬁed a variety
of p73b, p53 homolog, interacting proteins, such as Amphi-
physin IIb-1 [26] and p19ras [27] that are involved in p73b-med-
iated transactivity regulation and apoptosis. We also found
MAP1B-LC1 as a binding partner of p73b and conﬁrmed this
interaction in vivo and in vitro (our unpublished data). In
addition, MAP1B-LC1 also interacted with p53 (Fig. 1) and
speciﬁcally bound to the transactivation and oligomerization
domains of p53 (Fig. 3). Until now, several reports have dem-
onstrated that p53 has the potential to interact with the micro-
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Fig. 5. MAP1B-LC1 inhibits doxorubicin-induced apoptosis. (A) SH-SY5Y cells were transfected with GFP-tagged MAP1B-LC1 and were then
treated with 2 lM doxorubicin for 24 h. Immunoblot analysis of protein levels of p53, p21, and Bax was performed. b-Tubulin levels are shown as a
loading control. (B) After MAP1B-LC1 was transiently expressed, apoptotic DNA fragments were isolated from the untreated cells or cells treated
with 2 lM doxorubicin for 36 h, as indicated. (C) SH-SY5Y cells were transfected with GFP-MAP1B-LC1 or GFP empty vector as a control and
then untreated or treated with 2 lM doxorubicin for 24 h. Cells were then stained with Hoechst 33342 for the detection of apoptotic cells. The arrows
indicate that non-apoptotics cells and arrowheads indicate that apoptotic cells.
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the polymerized form of tubulin (microtubules) and is trans-
ported to the nucleus by the dynein motor complex. This inter-
action is lost after treatment with microtubule depolymerizing
drugs. In turn, the association of p53 with microtubule allows
for transport to the peri-nuclear region on microtubules and
subsequent nuclear import.
Furthermore, we tested the physiological signiﬁcance of the
binding between MAP1B-LC1 and p53 by assessing modula-
tions in the transcriptional activity by p53. MAP1B-LC1 sig-
niﬁcantly decreased this activity of p53 (Fig. 4A). Perhaps
MAP1B-LC1 might repress transcriptional activity of p53
through speciﬁc interactions with the transactivation and olig-
omerization domains of p53 (Fig. 3). MAP1B-LC1 binding to
the transactivation domain could prevent the association of
co-activators to p53, such as p300/CBP and PCAF. Further-
more, binding of MAP1B-LC1 to the oligomerization domain
may inhibit the formation of an activated p53-tetramer [30].
Thus, our ﬁndings provide a molecular and functional linkage
between MAP1B and p53 that likely inﬂuences cellular signal-
ing.
Doxorubicin is a representative cytotoxic drug that is eﬀec-
tive against neuroblastoma cells [31,32]. It has been previously
reported that p53 increases its expression level (both mRNA
and protein) and translocates to the nucleus to activate its
downstream eﬀectors genes, such as p21 and Bax, when cells
are treated with doxorubicin [25,33]. Our results indicated thatMAP1B-LC1 inhibits transcriptional activity of p53 and this
has led us to investigate the eﬀect of MAP1B-LC1 on p53-
dependent cell death by utilizing a p53 wild-type cell line,
SH-SY5Y. After doxorubicin treatment, the expression level
of MAP1B-LC1 was not changed, although MAP1B-LC1
did change its localization from the cytoplasm to the nucleus
(Fig. 2). Therefore, co-localization and interaction of
MAP1B-LC1 with p53 showed that MAP1B-LC1 represses
p53s activity in the nucleus. However, further studies are
needed to elucidate the mechanisms of MAP1B-LC1 transloca-
tion to the nucleus.
Despite intensive functional studies, the eﬀects of MAP1B
on cellular physiology have mostly focused on microtubule re-
lated mechanisms and other possible functions remain to be
fully elucidated. In this in mind, it is important to note that
our ﬁndings indicate a functional linkage between MAP1B
and p53 in vivo, showing that MAP1B-LC1 associates with
and negatively regulates p53 in SH-SY5Y neuroblastoma cells.
Our ﬁndings may aid in a molecular understanding of possible
defects in the regulation of p53 in chemoresistant neuroblas-
toma cells. Furthermore, these examinations should be consid-
ered when knockdown of MAP1B-LC1 is used as a cancer
therapeutic to enhance p53s apoptotic activity during chemo-
therapy
Acknowledgement: This work was supported by the Seoul R&BD
program and grants from Chung-Ang University.
2832 S.-Y. Lee et al. / FEBS Letters 582 (2008) 2826–2832References
[1] Gonzalez-Billault, C., Jimenez-Mateos, E.M., Caceres, A., Diaz-
Nido, J., Wandosell, F. and Avila, J. (2004) Microtubule-
associated protein 1B function during normal development,
regeneration, and pathological conditions in the nervous system.
J. Neurobiol. 58, 48–59.
[2] Riederer, B.M. (2007) Microtubule-associated protein 1B, a
growth-associated and phosphorylated scaﬀold protein. Brain
Res. Bull. 71, 541–558.
[3] Bouquet, C., Soares, S., von Boxberg, Y., Ravaille-Veron, M.,
Propst, F. and Nothias, F. (2004) Microtubule-associated protein
1B controls directionality of growth cone migration and axonal
branching in regeneration of adult dorsal root ganglia neurons. J.
Neurosci. 24, 7204–7213.
[4] Garcia, M.L. and Cleveland, D.W. (2001) Going new places using
an old MAP: tau, microtubules and human neurodegenerative
disease. Curr. Opin. Cell Biol. 13, 41–48.
[5] Gonzalez-Billault, C., Engelke, M., Jimenez-Mateos, E.M.,
Wandosell, F., Caceres, A. and Avila, J. (2002) Participation of
structural microtubule-associated proteins (MAPs) in the devel-
opment of neuronal polarity. J. Neurosci. Res. 67, 713–719.
[6] Takei, Y., Teng, J., Harada, A. and Hirokawa, N. (2000) Defects
in axonal elongation and neuronal migration in mice with
disrupted tau and map1b genes. J. Cell Biol. 150, 989–1000.
[7] Langkopf, A., Hammarback, J.A., Muller, R., Vallee, R.B. and
Garner, C.C. (1992) Microtubule-associated proteins 1A and
LC2. Two proteins encoded in one messenger RNA. J. Biol.
Chem. 267, 16561–16566.
[8] Togel, M., Eichinger, R., Wiche, G. and Propst, F. (1999) A 45
amino acid residue domain necessary and suﬃcient for proteolytic
cleavage of the MAP1B polyprotein precursor. FEBS Lett. 451,
15–18.
[9] Allen, E., Ding, J., Wang, W., Pramanik, S., Chou, J., Yau, V.
and Yang, Y. (2005) Gigaxonin-controlled degradation of
MAP1B light chain is critical to neuronal survival. Nature 438,
224–228.
[10] Dashiell, S.M., Tanner, S.L., Pant, H.C. and Quarles, R.H. (2002)
Myelin-associated glycoprotein modulates expression and phos-
phorylation of neuronal cytoskeletal elements and their associated
kinases. J. Neurochem. 81, 1263–1272.
[11] Franzen, R., Tanner, S.L., Dashiell, S.M., Rottkamp, C.A.,
Hammer, J.A. and Quarles, R.H. (2001) Microtubule-associated
protein 1B: a neuronal binding partner for myelin-associated
glycoprotein. J. Cell Biol. 155, 893–898.
[12] Bondallaz, P., Barbier, A., Soehrman, S., Grenningloh, G. and
Riederer, B.M. (2006) The control of microtubule stability in vitro
and in transfected cells by MAP1B and SCG10. Cell Motil.
Cytoskeleton 63, 681–695.
[13] Billups, D., Hanley, J.G., Orme, M., Attwell, D. and Moss, S.J.
(2000) GABAC receptor sensitivity is modulated by interaction
with MAP1B. J. Neurosci. 20, 8643–8650.
[14] Hanley, J.G., Jones, E.M. and Moss, S.J. (2000) GABA receptor
rho1 subunit interacts with a novel splice variant of the glycine
transporter, GLYT-1. J. Biol. Chem. 275, 840–846.
[15] Pattnaik, B., Jellali, A., Sahel, J., Dreyfus, H. and Picaud, S.
(2000) GABAC receptors are localized with microtubule-associ-
ated protein 1B in mammalian cone photoreceptors. J. Neurosci.
20, 6789–6796.[16] Cueille, N., Blanc, C.T., Riederer, I.M. and Riederer, B.M. (2007)
Microtubule-associated protein 1B binds glyceraldehyde-3-phos-
phate dehydrogenase. J. Proteome Res. 6, 2640–2647.
[17] Lerch-Gaggl, A.F., Sun, K. and Duncan, S.A. (2007) Light chain
1 of microtubule-associated protein 1B can negatively regulate the
action of Pes1. J. Biol. Chem. 282, 11308–11316.
[18] Levine, A.J. (1997) p53, the cellular gatekeeper for growth and
division. Cell 88, 323–331.
[19] Sengupta, S. and Harris, C.C. (2005) p53: traﬃc cop at the
crossroads of DNA repair and recombination. Nat. Rev. Mol.
Cell Biol. 6, 44–55.
[20] Harris, S.L. and Levine, A.J. (2005) The p53 pathway: positive
and negative feedback loops. Oncogene 24, 2899–2908.
[21] Kirsch, D.G. and Kastan, M.B. (1998) Tumor-suppressor p53:
implications for tumor development and prognosis. J. Clin.
Oncol. 16, 3158–3168.
[22] Frappaz, D. et al. (2000) LMCE3 treatment strategy: results in 99
consecutively diagnosed stage 4 neuroblastomas in children older
than 1 year at diagnosis. J. Clin. Oncol. 18, 468–476.
[23] Tweddle, D.A., Malcolm, A.J., Cole, M., Pearson, A.D. and
Lunec, J. (2001) p53 cellular localization and function in
neuroblastoma: evidence for defective G(1) arrest despite WAF1
induction in MYCN-ampliﬁed cells. Am. J. Pathol. 158, 2067–
2077.
[24] Cui, H., Schroering, A. and Ding, H.F. (2002) p53 mediates DNA
damaging drug-induced apoptosis through a caspase-9-dependent
pathway in SH-SY5Y neuroblastoma cells. Mol. Cancer Ther. 1,
679–686.
[25] Tweddle, D.A., Pearson, A.D., Haber, M., Norris, M.D., Xue, C.,
Flemming, C. and Lunec, J. (2003) The p53 pathway and its
inactivation in neuroblastoma. Cancer Lett. 197, 93–98.
[26] Kim, K.C., Kim, T.S., Kang, K.H. and Choi, K.H. (2001)
Amphiphysin IIb-1, a novel splicing variant of amphiphysin II,
regulates p73beta function through protein-protein interactions.
Oncogene 20, 6689–6699.
[27] Jeong, M.H., Bae, J., Kim, W.H., Yoo, S.M., Kim, J.W., Song,
P.I. and Choi, K.H. (2006) p19ras interacts with and activates p73
by involving the MDM2 protein. J. Biol. Chem. 281,
8707–8715.
[28] Giannakakou, P., Sackett, D.L., Ward, Y., Webster, K.R.,
Blagosklonny, M.V. and Fojo, T. (2000) p53 is associated with
cellular microtubules and is transported to the nucleus by dynein.
Nat. Cell Biol. 2, 709–717.
[29] Trostel, S.Y., Sackett, D.L. and Fojo, T. (2006) Oligomerization
of p53 precedes its association with dynein and nuclear accumu-
lation. Cell Cycle 5, 2253–2259.
[30] R.S. Foo et al. (2007) Regulation of p53 tetramerization and
nuclear export by ARC. Proc. Natl. Acad. Sci. USA 104, 20826–
20831.
[31] Matthay, K.K. (1997) Neuroblastoma: biology and therapy.
Oncology (Williston Park) 11, 1857–1866, (discussion 1869–1872,
1875).
[32] Matthay, K.K. (1998) Stage 4S neuroblastoma: what makes it
special? J. Clin. Oncol. 16, 2003–2006.
[33] Komarova, E.A., Zelnick, C.R., Chin, D., Zeremski, M.,
Gleiberman, A.S., Bacus, S.S. and Gudkov, A.V. (1997) Intra-
cellular localization of p53 tumor suppressor protein in gamma-
irradiated cells is cell cycle regulated and determined by the
nucleus. Cancer Res. 57, 5217–5220.
